- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Fruquintinib for previously treated metastatic colorectal cancer
Fruquintinib for previously treated metastatic colorectal cancer
Cancer
Gastrointestinal tract
16 September 2025
Published on 04 Jun 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Fruquintinib 1 mg and 5 mg capsules for treating patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy.
Funding status
Fruquintinib 1 mg and 5 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
Clinical indication, subsidy class and MediShield Life claim limit for fruquintinib are provided in the Annex.
Fruquintinib for previously treated metastatic colorectal cancer (Updated 16 Sep 2025)
